[HTML][HTML] Gout: An old disease in new perspective–A review

G Ragab, M Elshahaly, T Bardin - Journal of advanced research, 2017 - Elsevier
Gout is a picturesque presentation of uric acid disturbance. It is the most well understood
and described type of arthritis. Its epidemiology is studied. New insights into the …

Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options

T Bardin, P Richette - BMC medicine, 2017 - Springer
Gout, the most prevalent inflammatory arthritis worldwide, is associated with cardiovascular
and renal diseases, and is an independent predictor of premature death. The frequencies of …

Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian …

X Li, X Meng, M Timofeeva, I Tzoulaki, KK Tsilidis… - Bmj, 2017 - bmj.com
Objective To map the diverse health outcomes associated with serum uric acid (SUA) levels.
Design Umbrella review. Data sources Medline, Embase, Cochrane Database of Systematic …

Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review

CW Tsai, SY Lin, CC Kuo, CC Huang - PloS one, 2017 - journals.plos.org
Background Increasing evidence supports the association between hyperuricemia and
incident chronic kidney disease (CKD); however, there are conflicting data regarding the …

Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care …

T Bardin, RT Keenan, PP Khanna, J Kopicko… - Annals of the …, 2017 - ard.bmj.com
Objectives Determine the efficacy and safety of daily lesinurad (200 or 400 mg orally) added
to allopurinol in patients with serum uric acid (sUA) above target in a 12-month, randomised …

Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial

N Dalbeth, G Jones, R Terkeltaub… - Arthritis & …, 2017 - Wiley Online Library
Objective To investigate the efficacy and safety of lesinurad in combination with febuxostat in
a 12‐month phase III trial in patients with tophaceous gout. Methods Patients with serum …

A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout

LK Stamp, PT Chapman, ML Barclay… - Annals of the …, 2017 - ard.bmj.com
Objectives To determine the efficacy and safety of allopurinol dose escalation using a treat-
to-target serum urate (SU) approach. Methods A randomised, controlled, parallel-group …

Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies

SM Nielsen, EM Bartels, M Henriksen… - Annals of the …, 2017 - ard.bmj.com
Objectives Weight loss is commonly recommended for gout, but the magnitude of the effect
has not been evaluated in a systematic review. The aim of this systematic review was to …

Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study

AK Tausche, R Alten, N Dalbeth, J Kopicko… - …, 2017 - academic.oup.com
Objective To investigate the efficacy and safety of lesinurad, a selective uric acid
reabsorption inhibitor, in a 6 month, phase 3 clinical trial and extension study. Methods …

The unclosing premature mortality gap in gout: a general population-based study

MC Fisher, SK Rai, N Lu, Y Zhang… - Annals of the rheumatic …, 2017 - ard.bmj.com
Objective Gout, the most common inflammatory arthritis, is associated with premature
mortality. Whether this mortality gap has improved over time, as observed in rheumatoid …